Highlights

  • Second quarter net loss was USD 2,427 thousand against USD 3,221 thousand a year earlier.
  • Cash and cash equivalents were USD 4,198 thousand at June 30, 2026.
  • Total stockholders' Equity was USD 4,997 thousand against a Deficit of USD 1,272 thousand.
  • An ATM sales agreement signed May 26, 2026 covers up to USD 6,530,000.

Artelo Biosciences, Inc. (NASDAQ:ARTL) shares were trading near their all-time low at USD 2.05 on November 6, 2026, down 3.07% on the day. The company reported a second quarter net loss of USD 2,427 thousand and cash and cash equivalents of USD 4,198 thousand.

Artelo has not generated Revenue from product sales since its inception, according to its quarterly report, and has incurred operating losses and negative cash flows from operations.

Second Quarter and Six-Month Figures

Total operating expenses were USD 2,505 thousand against USD 3,150 thousand in the second quarter of 2025. The filing states that operating expenses were USD 2.5 million against USD 3.2 million and cites USD 1.0 million in lower Research and Development spending.

The net loss was USD 2,427 thousand against USD 3,221 thousand, or USD 0.89 per share against USD 16.86 per share. For the six months, the net loss was USD 5,385 thousand against USD 5,593 thousand, or USD 3.11 per share against USD 29.44 per share.

Balance Sheet

Total Assets were USD 6,459 thousand against USD 2,801 thousand at December 31, 2025. Total liabilities were USD 1,462 thousand against USD 4,073 thousand. Total stockholders' equity was USD 4,997 thousand against a deficit of USD 1,272 thousand.

The accumulated deficit was USD 68,400 thousand against USD 63,015 thousand. Net cash used in Operating Activities was USD 6,224 thousand for the six months against USD 2,111 thousand.

Share Count and Reverse Split

Shares outstanding rose to 4,188,400 at June 30, 2026 from 673,008 at December 31, 2025, and the registrant had 4,595,068 shares outstanding as of August 11, 2026. Weighted average shares were 2,712 thousand in the quarter against 191 thousand.

On June 12, 2025, the company filed a certificate of change in Nevada to effect a one-for-six Reverse Stock Split of its common stock.

ATM Program and Subsequent Issuance

On May 26, 2026, the company entered into an ATM Sales Agreement with an Investment bank, under which it may offer and sell common stock with an aggregate size stated in the filing as USD 6,530,000. After June 30, 2026, it issued 386,668 shares under the sales agreement for net proceeds of USD 354 thousand.

Cash Position

The filing reports cash, cash equivalents and investments of USD 4.2 million at June 30, 2026 against cash of USD 600 thousand at December 31, 2025. Cash at the beginning of the six-month period was USD 600 thousand, down from USD 2,338 thousand a year earlier.

Funding Arrangements

On January 30, 2026, the company entered into an equity purchase agreement with an investment fund. It gives the company the right, but not the obligation, to direct the fund to purchase up to USD 25.0 million of common stock, which the company can raise by a further USD 25.0 million once the initial amount is used, subject to conditions.

At the annual meeting on July 17, 2026, shareholders voted to increase the authorized number of common shares from 166,666,667 to 500,000,000.

Expense Outlook

The company expects to continue to incur research and development expenses for its drug candidates. It says the level of those expenses depends on the scope of pre-clinical and clinical development activities.